Onconic Therapeutics confirmed a complete response (CR) and a case of long-term survival of more than 40 months in a patient with metastatic pancreatic cancer using the next-generation dual-target anticancer drug candidate Nesuparib (JPI-547). The result draws attention because it comes from metastatic pancreatic cancer, which has a very poor prognosis.
Onconic Therapeutics said on the 1st that it presented phase 1b results of Nesuparib in metastatic and advanced pancreatic cancer at the American Society of Clinical Oncology (ASCO 2026), held in Chicago from the 29th of last month to the 2nd of this month (local time).
The trial enrolled 27 patients with metastatic or advanced pancreatic cancer and administered Nesuparib in combination with the existing standard therapies GemAbraxane or modified FOLFIRINOX (mFOLFIRINOX).
In the GemAbraxane combination cohort, the objective response rate (ORR) was 53.8% and the disease control rate (DCR) was 92.3%. The median overall survival (mOS) was 14.2 months, exceeding the 8.5 months reported in the prior global GemAbraxane study (MPACT). Of the 13 patients, 12 (92.3%) surpassed the median survival of the standard therapy.
In particular, one patient who achieved a complete response, with target lesions disappearing completely, has survived for more than 40 months as of late December last year, and another patient has continued to survive for more than 24 months. In the KRAS-mutant subgroup, the objective response rate was 75% and the disease control rate was 100%. The company said the treatment effect was also observed in patients without BRCA mutations.
Nesuparib is a dual-target anticancer drug candidate that simultaneously inhibits tankyrase and PARP in cancer cells. It has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) in three cancer types, including pancreatic cancer, and a phase 2 trial as a first-line therapy for metastatic and advanced pancreatic cancer is underway.
Kim Jon, CEO of Onconic Therapeutics, said, "We confirmed cases of survival for more than 40 months and maintenance of complete response in patients with metastatic pancreatic cancer," adding, "We will further validate the treatment potential through the ongoing phase 2 trial."